CoChat

Report of the AAPS Guidance Forum on the FDA draft guidance for industry:“drug products, including biological products, that contain nanomaterials”

Open access

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

To guide developers of innovative and generic drug products that contain nanomaterials, the U.S. Food and Drug Administration issued the draft guidance for industry titled: "Drug Products, Including Biological Products, that Contain Nanomaterials" in December 2017. During the AAPS Guidance Forum on September 11, 2018, participants from industry, academia, and regulatory bodies discussed this draft guidance in an open setting. Two questions raised by the AAPS membership were discussed in more detail: what is the appropriate regulatory pathway for approval of drug products containing nanomaterials, and how to determine critical quality attributes (CQAs) for nanomaterials? During the meeting, clarification was provided on how the new FDA center-led guidance relates to older, specific nanomaterial class, or specific product-related guidances. The lively discussions concluded with some clear observations and recommendations: (I) Important lessons can be learned from how CQAs were determined for, e.g., biologics. (II) Publication of ongoing scientific discussions on strategies and studies determining CQAs of drug products containing nanomaterials will significantly strengthen the science base on this topic. Furthermore, (III) alignment on a global level on how to address new questions regarding nanomedicine development protocols will add to efficient development and approval of these much needed candidate nanomedicines (innovative and generic). Public meetings such as the AAPS Guidance Forum may serve as the place to have these discussions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1208/s12248-019-0329-7

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Distribution of nanomaterials use in drug products from 1973 to 2015. Breakdown of the types of nanomaterials used in drug products. The nanotechnology terminologies do not represent any implication for CDER drug product labeling and were used only to describe/interpret the type of nanomaterials in identified drug products for the purpose of this analysis (adapted from 4)
Fig. 1 Distribution of nanomaterials use in drug products from 1973 to 2015. Breakdown of the types of nanomaterials used in drug products. The nanotechnology terminologies do not represent any implication for CDER drug product labeling and were used only to describe/interpret the type of nanomaterials in identified drug products for the purpose of this analysis (adapted from 4)CC BY · PubMed Central
Fig. 2 Example on how FDA guidances on the same general subject relate to each other
Fig. 2 Example on how FDA guidances on the same general subject relate to each otherCC BY · PubMed Central
Fig. 3 The complex drug landscape (illustrative). Drug products are positioned on the basis of the challenge to assess pharmaceutical equivalence (PE) and bioequivalence (BE) of two drug products (i.e., the reference product and its generic version). Conventional low-molecular-weight drugs that can be fully characterized are shown in orange; demonstration of PE and BE is relatively simple. Biologics are shown in green, NBCDs are shown in blue, and other complex drugs are shown in gray. Albumin-bound nanoparticles and low-molecular-weight heparins are blue with a green outline (classification of these drugs varies across the globe). Adapted from Hussaarts et al. (10)
Fig. 3 The complex drug landscape (illustrative). Drug products are positioned on the basis of the challenge to assess pharmaceutical equivalence (PE) and bioequivalence (BE) of two drug products (i.e., the reference product and its generic version). Conventional low-molecular-weight drugs that can be fully characterized are shown in orange; demonstration of PE and BE is relatively simple. Biologics are shown in green, NBCDs are shown in blue, and other complex drugs are shown in gray. Albumin-bound nanoparticles and low-molecular-weight heparins are blue with a green outline (classification of these drugs varies across the globe). Adapted from Hussaarts et al. (10)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 131

Metadata

Authors
de Vlieger, J. S. B., Crommelin, D. J. A., Tyner, K., Drummond, D. C., Jiang, W., McNeil, S. E., Neervannan, S., Crist, R. M., & Shah, V. P.
Affiliations
  • Utrecht University (NL)
  • United States Food and Drug Administration (US)
  • Merrimack Pharmaceuticals (United States) (US)
  • Frederick National Laboratory for Cancer Research (US)
Venue
The AAPS Journal
Published
2019-04-17
Volume
21
Issue
4
Pages
56-56
ISSN
1550-7416 (ISSN-L)
OpenAlex
W2936171216
Cited by
100
References
16
Citations by year
2026: 37 · 2025: 20 · 2024: 6 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 7 · 2019: 3
FWCI
1.98
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • The AAPS Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health and Human Services (HHSN261200800001E)
  • National Cancer Institute (No. HHSN261200800001E, Contract No.,HHSN261200800001E, HHSN261200800001E))
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Physical Sciences › Materials Science › General Materials Science › Nanotechnology research and applications
Keywords
nanomedicine regulation, critical quality attributes, regulatory approval pathways, generic drugs, biologics, regulatory science
MeSH terms
Biological Products, Drug Industry, United States, United States Food and Drug Administration, Drugs, Generic, Drug Approval, Guidelines as Topic, Government Regulation, Nanostructures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Report of the AAPS Guidance Forum on the FDA draft guidance for industry:“drug products, including biological products, that contain nanomaterials”. https://app.cochat.ai/papers/10.1208/s12248-019-0329-7
The paper
de Vlieger, J. S. B., Crommelin, D. J. A., Tyner, K., Drummond, D. C., Jiang, W., McNeil, S. E., Neervannan, S., Crist, R. M., & Shah, V. P. (2019). Report of the AAPS Guidance Forum on the FDA draft guidance for industry:“drug products, including biological products, that contain nanomaterials”. The AAPS Journal. https://doi.org/10.1208/s12248-019-0329-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.